Addenbrooke’s infectious disease consultant and Cambridge University Professor Ravi Gupta is named in this year’s TIME magazine 100 list of the world's most influential people. He said:
It is a huge and unexpected honour to be included in this year’s TIME 100 list of influential individuals worldwide.Prof Ravi Gupta
This accolade is in recognition of work on the London Patient, Adam Castillejo, in whom we demonstrated cure of HIV infection by stem cell transplantation, the second such case in history.
"This was an incredible journey spanning multiple countries over five years. Now, with over a decade working in HIV virology, my team has been able to draw on this experience to fight Covid-19 on multiple fronts, from testing to understanding why people become so sick.
Since February this year, Prof Gupta and his team at the Cambridge Institute for Therapeutic Immunology and Infectious Diseases (CITIID) have been applying all their expertise to help diagnose and treat Covid, including developing a new rapid point-of-care test for Covid-19 using SAMBA II machines. These are currently in use at Addenbrooke’s and are crucial to providing a fast diagnosis in order to provide the best possible care for patients.
Dr Ashley Shaw, Medical Director at Cambridge University Hospitals (CUH), which runs Addenbrooke’s, said:
This is an incredible achievement, and all of us at CUH are very proud of Ravi.Dr Ashley Shaw, Medical Director, CUH
We are delighted to have world-class researchers like him, and including many others, working in our hospital helping us save patients’ lives.
“Never has it been more important that clinicians work hand-in-hand with scientists. Ravi and his colleagues at Cambridge University have been alongside us from the very start of the Covid crisis making sure that scientific developments transfer from the lab bench to the patient’s bedside as quickly as humanly possible.”
As well as his roles at Addenbrooke’s and Cambridge University, Prof Gupta holds a faculty position at the Africa Health Research Institute (AHRI) where his work is focussed on understanding the genetic and biological properties of drug resistant HIV in South Africa, where it is estimated that 10% or more patients experience treatment failure.